Adrenergic Uptake Inhibitors - Adverse effects
Research News and Information

Sunday, November 22, 2009

[Attention Deficit Hyperactivity Disorder (ADHD) and road traffic - special considerations for the treatment of adolescents with ADHD]

30 Aug 2009 Attention Deficit Hyperactivity Disorder (ADHD) is not only a childhood disorder but symptoms persist into adolescence and adulthood in approximately one third of the patients. Especially inattention and poor concentration impair driving performance ... Read more...

Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions.

30 Aug 2009 Attention-deficit hyperactivity disorder (ADHD) is one of the most common neurobehavioural disorders in children. It has been shown that as many as 85% of patients with ADHD have at least one psychiatric co-morbidity, and approximately 60% have at ... Read more...

Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.

30 Aug 2009 OBJECTIVES: To examine the efficacy and tolerability of atomoxetine (ATX) in improving cognitive performance of patients with Alzheimer dementia. DESIGN: A randomized, double-blind, placebo (PLA)-controlled, parallel-groups study, starting with a ... Read more...

Latest indexed articles for 'Adrenergic Uptake Inhibitors - Adverse effects'

These are the very latest articles for this heading:

• [Attention Deficit Hyperactivity Disorder (ADHD) and road traffic - special considerations for the treatment of adolescents with ADHD] 30 Aug 2009
• Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions. 30 Aug 2009
• Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study. 30 Aug 2009
• Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial. 29 Jun 2009
• Second opinions improve ADHD prescribing in a medicaid-insured community population. 29 Jun 2009
• Treatment of chorea associated with Huntington's disease: focus on tetrabenazine. 29 Jun 2009
• Milnacipran (savella) for fibromyalgia. 13 Jun 2009
• Atomoxetine hydrochloride-associated transient psychosis in an adolescent with attention-deficit/hyperactivity disorder and mild mental retardation. 30 May 2009
• Cannabis coadministration potentiates the effects of "ecstasy" on heart rate and temperature in humans. 11 May 2009
• [Therapeutic use of tetrabenazine] 29 Apr 2009
• Is suicidality serious? 29 Apr 2009
• A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. 5 Apr 2009
• Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder. 30 Mar 2009
• [Symptomatic hyponatremia after ecstasy use] 19 Mar 2009
• The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. 30 Jan 2009
• Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. 30 Jan 2009
• Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. 28 Jan 2009
• Noradrenergic stimulation and motor performance: differential effects of reboxetine on movement kinematics and visuomotor abilities in healthy human subjects. 20 Jan 2009
• Adverse effects in neonates exposed to SSRIs and SNRI in late gestation--Motherisk Update 2008. 20 Jan 2009
• Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents. 14 Jan 2009

See a longer list of these articles.

Technical information about 'Adrenergic Uptake Inhibitors'

Definition: Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.

Registry Number: 0

Descriptor UI: D018759

Alternative terms: Adrenergic Uptake Inhibitors; Reuptake Inhibitors, Adrenergic; Inhibitors, Adrenergic Uptake; Uptake Inhibitors, Adrenergic; Inhibitors, Adrenergic Reuptake; Adrenergic Reuptake Inhibitors;

Related Mesh Headings: Amphetamines; Antidepressive Agents, Tricyclic; Dopamine Uptake Inhibitors;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.519.625.050.601; D27.505.519.625.600.050; D27.505.696.577.050.601; D27.505.696.577.600.050;

History Note: 95

Technical Notes: GEN or unspecified; prefer specifics; DF: ADREN UPTAKE INHIB